Effect of Rosuvastatin on Prognosis of Clinical Response in Acute Ischemic Stroke Patients(REPAIRS)
Status:
Unknown status
Trial end date:
2018-09-01
Target enrollment:
Participant gender:
Summary
This study is randomized, open-lable, parallel-group and comparator-controlled. 456
consecutive patients with acute ischemic stroke admitted within the first 72 hours after
onset of symptoms will be studied. Those patients who will be randomly assigned to receive 2
different treatment for the first 3 days of hospitalization(non-statin-therapy group) or to
immediately receive rosuvastatin orally at a dose of 20mg daily (statin-therapy group). From
the fourth day onward, rosuvastatin 10 mg daily will be administered in all patients. The
total trial will be continued 12 months.
mRS will be investigated at baseline, 3rd month, 12th month ;MMSE and Montreal tests will be
investigated at baseline and 12th month. Laboratory data including serum lipids, Fg and
hs-CRP.Among these, serum lipids will be tested at baseline, 8th day, 3rd month, 6th
month,and 12th month; hs-CRP will be tested at baseline and 8th day, 3rd month; Fg will be
tested at baseline, 8th day, 3rd month. Safety will be also assessed by adverse event reports
and clinical laboratory data including CK-MB, renal and hepatic function at 3rd month, 6th
month,12th month.
Phase:
Phase 4
Details
Lead Sponsor:
Second Affiliated Hospital of Soochow University
Collaborators:
AstraZeneca National Natural Science Foundation of China Taicang No.1 People's hospital Taicang No.1 People’s hospital